Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2002

View Archived Issues

New dosage form of Atrix's Leuprogel licensed in by Sanofi-Synthelabo

InKine submits chemistry supplement for new formulation of Visicol for colon cleansing

SpectRx acquires Sterling Medivations

Unexpected gene regulatory effects by probucol and BO-653

Pharmacia granted rights to foam delivery technology for use with Rogaine

Phase IIb clinical trial of NBI-6024 in diabetes set to commence

Pretarget product candidates in phase Ia clinical trials

MAP acquires European rights for Dopascan Injection for Parkinson's disease imaging

Genzyme Genetics acquires diagnostic cancer rights from Genzyme Molecular Oncology

Uridine derivatives with antibiotic properties reported by Aventis

Chugai researchers design vitamin D3 analogues with antipsoriatic activity

Aventis discloses novel vitronectin receptor antagonists

Kyowa Hakko and Lilly report new potent antitumor compounds

Suntory presents new compounds for the treatment of osteoporosis and other bone diseases

Scientists at Sumitomo identify novel PARP inhibitors

Novel betacin antibiotic described by Versicor

SCAP ligands: a promising new class of hypolipidemic drugs

Peptidomimetic exhibits broad antimicrobial and endotoxin-neutralizing activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...